140 related articles for article (PubMed ID: 2804562)
1. B5 tumour marker and urine cytology in diagnosis and follow-up of transitional cell bladder cancer.
Malpani K; Metcalfe SM; Hinchliffe A
Br J Urol; 1989 Sep; 64(3):257-62. PubMed ID: 2804562
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of urinary cytology in the detection of recurrent bladder tumours.
Baltaci S; Süzer O; Ozer G; Bedük Y; Göğüş O
Int Urol Nephrol; 1996; 28(5):649-53. PubMed ID: 9061424
[TBL] [Abstract][Full Text] [Related]
3. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
5. [Urine cytology and urine markers. Significance for clinical practice].
Tritschler S; Zaak D; Knuechel R; Stief CG
Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
[TBL] [Abstract][Full Text] [Related]
6. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
7. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
8. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma.
Meuleman EJ; Delaere KP
Br J Urol; 1988 Aug; 62(2):150-3. PubMed ID: 3408887
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder.
Giella JG; Ring K; Olsson CA; Karp FS; Benson MC
J Urol; 1992 Aug; 148(2 Pt 1):293-6. PubMed ID: 1635121
[TBL] [Abstract][Full Text] [Related]
13. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
14. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
15. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
Kelloniemi E; Rintala E; Finne P; Stenman UH;
Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
[TBL] [Abstract][Full Text] [Related]
17. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
18. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
Keller AK; Jensen JB
Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
[TBL] [Abstract][Full Text] [Related]
19. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
20. A new tumour marker tested in 98 patients with bladder carcinoma.
Metcalfe SM; Jamieson NV
Ann R Coll Surg Engl; 1984 Nov; 66(6):399-401. PubMed ID: 6508158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
